Skip to content
Triangle logo TriangleGet started
← Full study record

NCT03947255 · OUTCOME

Progression-free Survival Per Investigator Assessment According to Modified Lugano Response Criteria

A Study of Retreatment With Brentuximab Vedotin in Subjects With Classic Hodgkin Lymphoma or CD30-expressing Peripheral T Cell Lymphoma · Source last updated 2023-10-13

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure
MEDIAN
Unit
Months
Interval / dispersion
95% Confidence Interval
Time frame
Up to 18.3 months

What was measured

PFS is defined as the time from start of study treatment to first documentation of objective tumor progression according to the Modified Lugano Criteria for Response Assessment (Cheson 2007) or to death due to any cause, whichever comes first.

Analysis population: The full analysis set includes participants who received at least one dose of study treatment.

Groups in this outcome

Classic Hodgkin Lymphoma

Participants with classic Hodgkin lymphoma

PTCL

Participants with peripheral T cell lymphoma

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

GroupSource count
Classic Hodgkin Lymphoma5
PTCL6

Reported measurements

Source class 1
Values in Months · Interval/dispersion: 95% Confidence Interval
GroupValueSpreadLowerUpperComment
Classic Hodgkin Lymphoma6.5Not reported3.2NANot enough events to calculate Upper Limit.
PTCLNANot reported1.1NANot enough events to calculate Median or Upper Limit.
Complete source fields
classes
  1. categories
    1. measurements
      1. comment
        Not enough events to calculate Upper Limit.
        group Id
        OG000
        lower Limit
        3.2
        upper Limit
        NA
        value
        6.5
      2. comment
        Not enough events to calculate Median or Upper Limit.
        group Id
        OG001
        lower Limit
        1.1
        upper Limit
        NA
        value
        NA
denoms
  1. counts
    1. group Id
      OG000
      value
      5
    2. group Id
      OG001
      value
      6
    units
    Participants
description
PFS is defined as the time from start of study treatment to first documentation of objective tumor progression according to the Modified Lugano Criteria for Response Assessment (Cheson 2007) or to death due to any cause, whichever comes first.
dispersion Type
95% Confidence Interval
groups
  1. description
    Participants with classic Hodgkin lymphoma
    id
    OG000
    title
    Classic Hodgkin Lymphoma
  2. description
    Participants with peripheral T cell lymphoma
    id
    OG001
    title
    PTCL
param Type
MEDIAN
population Description
The full analysis set includes participants who received at least one dose of study treatment.
reporting Status
POSTED
time Frame
Up to 18.3 months
title
Progression-free Survival Per Investigator Assessment According to Modified Lugano Response Criteria
type
SECONDARY
unit Of Measure
Months

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice